Open Research Studies at Dell Children’s Blood and Cancer Center

Research studies are constantly evolving, please reach out to our research team to verify status and availability.

  • PXA Study – Clinical, radiologic, and molecular characteristics of anaplastic pleomorphic xanthoastrocytomas
  • ADVL1711 – A phase 1-2 study of lenvatinib in combination with everolimus in recurrent and refractory pediatric solid tumors, including CNS tumors
  • MEMMAT – Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial; A phase 2 study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma and ATRT
  • ACNS1422 – A phase 2 study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients
  • APEC1621 (and associated match studies) – NCI-COG pediatric MATCH (Molecular Analysis for Therapy Choice) master version control protocol for all pediatric tumors
  • APEC1621J – NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
  • ADVL1921 – Phase 1 study to evaluate the safety and pharmacokinetics of Palbociclib Ibrance® in combination with Irinotecan and Temozolomide in pediatric patients with recurrent or refractory solid tumors (including brain tumors)
  • APEC1621K – NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH – Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
  • APEC1621M – NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 subprotocol of Tipifarnib
  • ACNS1723 – A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
  • BCC-016: medulloblastoma study (in process of opening)